Den Boer M L, Kapaun P, Pieters R, Kazemier K M, Janka-Schaub G E, Veerman A J
Department of Paediatric Haematology/Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.
Br J Haematol. 1999 Jun;105(4):876-82. doi: 10.1046/j.1365-2141.1999.01440.x.
Contradictory data have been reported about the prognostic value of myeloid antigen co-expression (My+) in childhood acute lymphoblastic leukaemia (ALL). In the present study the methyl thiazol tetrazoliumbromide (MTT) assay was used to compare the in vitro cytotoxicity of 14 drugs between 60 My+ (CD13+ and/or CD33+) and 107 My- ALL children at initial diagnosis. P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), major vault protein/lung resistance protein (LRP) and the intracellular daunorubicin concentration were studied by flow cytometry. My+ ALL samples were significantly more resistant, i.e. between 1.1- and 2.9-fold, to daunorubicin, doxorubicin, idarubicin, mitoxantrone, vincristine, 6-thioguanine, 6-mercaptopurine, teniposide, etoposide and ifosfamide compared with My- ALL samples. My- and My+ ALL did not significantly differ in sensitivity to prednisolone, dexamethasone, L-asparaginase and cytarabine. Comparable results were found when only common and preB ALL cases were analysed. Drug resistance in My+ ALL was not related to increased expression of P-gp, MRP or LRP compared with My- ALL (ratio My+/My-:P-gp 0.8, MRP 1.0, LRP 1.1). Accumulation and retention of daunorubicin did not significantly differ between My- and My+ ALL cells (ratio My+/My-: accumulation 1.2, retention 1.3). Therefore the nature of drug resistance in My+ ALL remains unknown. The lack of prognostic value for My+ in childhood ALL may be explained by the responsiveness of My+ ALL to glucocorticoids, L-asparaginase and cytarabine. In addition, the currently intensive treatment regimens may apply drug doses which are simply high enough to overcome the mild resistance to anthracyclines, mitoxantrone, vincristine, thiopurines, epipodophyllotoxins and ifosfamide in childhood My+ ALL.
关于髓系抗原共表达(My+)在儿童急性淋巴细胞白血病(ALL)中的预后价值,已有相互矛盾的数据报道。在本研究中,采用甲基噻唑四氮唑溴盐(MTT)法比较了60例My+(CD13+和/或CD33+)和107例My- ALL儿童初诊时14种药物的体外细胞毒性。通过流式细胞术研究了P-糖蛋白(P-gp)、多药耐药相关蛋白(MRP)、主要穹窿蛋白/肺耐药蛋白(LRP)以及细胞内柔红霉素浓度。与My- ALL样本相比,My+ ALL样本对柔红霉素、阿霉素、伊达比星、米托蒽醌、长春新碱、6-硫鸟嘌呤、6-巯基嘌呤、替尼泊苷、依托泊苷和异环磷酰胺的耐药性明显更强,即耐药倍数在1.1至2.9倍之间。My-和My+ ALL对泼尼松龙、地塞米松、L-天冬酰胺酶和阿糖胞苷的敏感性无显著差异。仅分析普通型和前B型ALL病例时,也得到了类似结果。与My- ALL相比,My+ ALL中的耐药性与P-gp、MRP或LRP表达增加无关(My+/My-比值:P-gp为0.8,MRP为1.0,LRP为1.1)。My-和My+ ALL细胞之间柔红霉素的蓄积和滞留无显著差异(My+/My-比值:蓄积为1.2,滞留为1.3)。因此,My+ ALL中耐药性的本质尚不清楚。儿童ALL中My+缺乏预后价值可能是由于My+ ALL对糖皮质激素、L-天冬酰胺酶和阿糖胞苷有反应。此外,目前的强化治疗方案所应用的药物剂量可能高到足以克服儿童My+ ALL对蒽环类药物、米托蒽醌、长春新碱、硫嘌呤、表鬼臼毒素和异环磷酰胺的轻度耐药性。